DK3634411T3 - Fremgangsmåder til behandling af NASH og til forebyggelse af NASH-induceret HCC - Google Patents

Fremgangsmåder til behandling af NASH og til forebyggelse af NASH-induceret HCC Download PDF

Info

Publication number
DK3634411T3
DK3634411T3 DK18739929.0T DK18739929T DK3634411T3 DK 3634411 T3 DK3634411 T3 DK 3634411T3 DK 18739929 T DK18739929 T DK 18739929T DK 3634411 T3 DK3634411 T3 DK 3634411T3
Authority
DK
Denmark
Prior art keywords
nash
approaches
prevention
treatment
induced hcc
Prior art date
Application number
DK18739929.0T
Other languages
English (en)
Inventor
Mark Anthony Febbraio
Jozsef Mandl
Original Assignee
N Gene Res Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Laboratories Inc filed Critical N Gene Res Laboratories Inc
Application granted granted Critical
Publication of DK3634411T3 publication Critical patent/DK3634411T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK18739929.0T 2017-06-08 2018-06-08 Fremgangsmåder til behandling af NASH og til forebyggelse af NASH-induceret HCC DK3634411T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516681P 2017-06-08 2017-06-08
PCT/IB2018/054155 WO2018225026A1 (en) 2017-06-08 2018-06-08 Methods for treating nash and for preventing nash-induced hcc

Publications (1)

Publication Number Publication Date
DK3634411T3 true DK3634411T3 (da) 2023-12-04

Family

ID=62875071

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18739929.0T DK3634411T3 (da) 2017-06-08 2018-06-08 Fremgangsmåder til behandling af NASH og til forebyggelse af NASH-induceret HCC

Country Status (13)

Country Link
US (1) US11357768B2 (da)
EP (1) EP3634411B1 (da)
JP (1) JP7270979B2 (da)
KR (2) KR102636934B1 (da)
CN (1) CN110719780A (da)
AU (2) AU2018282124B2 (da)
DK (1) DK3634411T3 (da)
ES (1) ES2966459T3 (da)
FI (1) FI3634411T3 (da)
HU (1) HUE064743T2 (da)
PL (1) PL3634411T3 (da)
PT (1) PT3634411T (da)
WO (1) WO2018225026A1 (da)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
JP2004182638A (ja) 2002-12-03 2004-07-02 Yakult Honsha Co Ltd 炎症性疾患又は悪性腫瘍の予防治療剤
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
WO2009070781A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
RU2654231C2 (ru) 2011-06-28 2018-05-17 Алтернатив Инновейтив Текнолоджиз, Ллц Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты)
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition

Also Published As

Publication number Publication date
FI3634411T3 (fi) 2023-12-15
JP7270979B2 (ja) 2023-05-11
RU2019144060A3 (da) 2021-10-20
PL3634411T3 (pl) 2024-03-11
KR20200013704A (ko) 2020-02-07
EP3634411B1 (en) 2023-09-20
US11357768B2 (en) 2022-06-14
KR102636934B1 (ko) 2024-02-16
PT3634411T (pt) 2023-11-28
RU2019144060A (ru) 2021-07-09
AU2018282124A1 (en) 2020-01-02
WO2018225026A1 (en) 2018-12-13
AU2024266953A1 (en) 2024-12-19
AU2018282124B2 (en) 2024-09-19
JP2020523296A (ja) 2020-08-06
KR20240023698A (ko) 2024-02-22
HUE064743T2 (hu) 2024-04-28
EP3634411A1 (en) 2020-04-15
US20200179363A1 (en) 2020-06-11
ES2966459T3 (es) 2024-04-22
CN110719780A (zh) 2020-01-21

Similar Documents

Publication Publication Date Title
DK3129018T3 (da) Behandling af NAFLD og NASH
IL252026B (en) Humanized anti-complement factor c1q antibodies and uses thereof
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3372229T3 (da) Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3371152T3 (da) Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
IL283200A (en) Combination treatment of nafld and nash
DK3444010T3 (da) Pklr-inhibering i behandlingen af nafld og hcc
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3174559T3 (da) Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3326635T3 (da) Behandling og forebyggelse af forkølelse ved hjælp af povidon-iod
DK3386507T3 (da) Metoder og sammensætninger til behandling af mavesår
DK3258964T3 (da) Detektion og behandling af maligne tumorer i CNS
DK3142655T3 (da) Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban
DK3220908T3 (da) Sammensætninger og fremgangsmåder til behandling af endometriose
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri